IMRX - PR: Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS
IMRX - PR: Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition Link To Press Release
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.